The pharmacology of CGS 25462: a potent, orally bioavailable, long-acting inhibitor of neutral endopeptidase 24.11
Trapani, A.J.; De Lombaert, S.; Erion, M.D.; Ghai, R.D.; Peppard, J.V.; Lappe, R.W.; Worcel, M.
Journal of Hypertension. Suppl Official Journal of the International Society of Hypertension 11(5): S220-S221
1993
ISSN/ISBN: 0952-1178 PMID: 8158354 Document Number: 406201
Document emailed within 1 workday
Related Documents
Trapani, A.J.; De Lombaert, S.; Kuzmich, S.; Jeng, A.Y. 1995: Inhibition of big ET-1-induced pressor response by an orally active dual inhibitor of endothelin-converting enzyme and neutral endopeptidase 24.11 Journal of Cardiovascular Pharmacology 26(Suppl): S69-S71Shimamoto, K.; Ura, N.; Iimura, O. 1994: The natriuretic mechanisms of neutral endopeptidase inhibitor in rats Brazilian Journal of Medical and Biological Research 27(8): 1965-1973
Campbell, D.J.; Anastasopoulos, F.; Duncan, A.M.; James, G.M.; Kladis, A.; Briscoe, T.A. 1998: Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats Journal of Pharmacology and Experimental Therapeutics 287(2): 567-577
Richard, V.; Lecomte, J.M.; Thuillez, C. 1993: Systemic and regional hemodynamic effects of a new angiotensin converting enzyme and neutral endopeptidase mixed inhibitor, alatriopril, in the dog Archives des Maladies du Coeur et des Vaisseaux 86(8): 1275-1279
Sharkovska, Y.; Kalk, P.; Karoline von Websky; Relle, K.; Pfab, T.; Alter, M.; Fischer, Y.; Hocher, B. 2011: Renoprotective Effects of Combined Endothelin-Converting Enzyme/Neutral Endopeptidase Inhibitor SLV338 in Acute and Chronic Experimental Renal Damage Clinical Laboratory 57(7-8): 507-515
Yaksh, T.L.; Sabbe, M.B.; Lucas, D.; Mjanger, E.; Chipkin, R.E. 1991: Effects of [N-(L-(1-carboxy-2-phenyl)ethyl]-L-phenylalanyl-beta-alanine (SCH32615), a neutral endopeptidase (enkephalinase) inhibitor, on levels of enkephalin, encrypted enkephalins and substance P in cerebrospinal fluid and plasma of primates Journal of Pharmacology and Experimental Therapeutics 256(3): 1033-1041
Liao, P.-A.; Pan, S.-W.; Chen, C.-Y.; Deng, C.-Y.; Dong, Y.-H. 2023: Prescription Patterns of new use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids International Journal of Chronic Obstructive Pulmonary Disease 18: 553-563
Katz, L.B.; Scott, C.K.; Shriver, D.A. 1986: Pharmacological comparison of ORF 17910, a potent, long-acting histamine H2-receptor antagonist, to cimetidine and ranitidine Journal of Pharmacology and Experimental Therapeutics 238(2): 587-593
Djokić, T.D. 1992: The role of enkephalinase (neutral endopeptidase) in neurogenic inflammation of the respiratory tract Glas. Srpska Akademija Nauka i Umetnosti. Odeljenje Medicinskih Nauka 42: 107-121
Le Moual, H.; Beaumont, A.; Roques, B.P.; Crine, P.; Boileau, G. 1992: Identification of two arginine residues involved in the binding of substrate to neutral endopeptidase 24-11 Matrix . Supplement 1: 99
Tamburini, P.P.; Koehn, J.A.; Gilligan, J.P.; Charles, D.; Palmesino, R.A.; Sharif, R.; McMartin, C.; Erion, M.D.; Miller, M.J. 1989: Rat vascular tissue contains a neutral endopeptidase capable of degrading atrial natriuretic peptide Journal of Pharmacology and Experimental Therapeutics 251(3): 956-961
Skryzdło-Radomańska, B.; Pollard, H.; Schabowski, J.; Radwan, P.; Celiński, K.; Pokora, J.; Gespach, C. 1994: Activity of enkephalinase (EC.3.4.24.11). Neutral endopeptidase (NEP)in human digestive tract epithelial cells Wiadomosci Lekarskie 47(1-2): 13-17
Bartuś, J.B.; Chłopicki, S. 2003: Effect of neutral endopeptidase inhibition on vascular response induced by exogenous angiotensin i in the isolated rat lung Polish Journal of Pharmacology 55(6): 1071-1078
Winkler, G.; Hajós, P.; Pál, B.; Tóth, J. 1997: Experience with benazepril, a long-acting ACE inhibitor, in the management of diabetic hypertension Orvosi Hetilap 138(27): 1737-1742
Inagaki, A. 2016: Safety of Long-acting Injectable Antipsychotics Is Long-acting Injection a High-risk Treatment Option? Seishin Shinkeigaku Zasshi 118(8): 589-597
Belsey, E.M. 1991: Menstrual bleeding patterns in untreated women and with long-acting methods of contraception. Task Force on Long-Acting Systemic Agents for Fertility Regulation Advances in contraception: the official journal of the Society for the Advancement of Contraception 7(2-3): 257-270
Belsey, E.M. 1991: Menstrual bleeding patterns in untreated women and with long-acting methods of contraception. Task Force on Long-Acting Systemic Agents for Fertility Regulation Advances in contraception: the official journal of the Society for the Advancement of Contraception 7(2-3): 257-270
Suzuki, Y. 2016: The Safety of Using Long-acting Injections : from an Opposing Position-Is it Better to Administer Long-acting Injections? Seishin Shinkeigaku Zasshi 118(8): 584-588
Yokono, K. 2001: Recent trends of development of rapid-acting and long-acting human insulin analogues--its biological characteristics and clinical availability Nihon Rinsho. Japanese Journal of Clinical Medicine 59(11): 2127-2133
Fukushima, H.; Nakamura, M.; Yamamoto, H. 1977: Pharmacology of 9-gamma-methylaminopropyl-9,10-dihydro-9,10-methanoanthracene-HCl (ID-9206-HCl), a new potent antidepressant Archives Internationales de Pharmacodynamie et de Therapie 229(1): 163-176